Abstract
PurposeThe use process for chimeric antigen receptor T (CAR-T) cell drugs is complex and has been associated with a number of potentially severe complications, which requires management by a multidisciplinary team. Pharmacists are a key element in the team and have roles and responsibilities. Our objective was to develop a structured and practical guide that supports hospital pharmacist responsibilities and defines specific activities in a CAR-T cell therapy program, specifically in Europe.MethodsA literature review was performed, and the recommendations related to pharmacy practice in CAR-T therapy programs were analyzed. A multidisciplinary team was assembled, and meetings were held to address the key tasks in the CAR-T cells’ management process and to create the guide, based on national and international recommendations and in expert’s opinions.ResultsThe multidisciplinary team defined the following key tasks and issued recommendations to improve patient safety, treatment efficacy, and quality: patient selection and evaluation, CAR-T cell drug order to manufacturer, apheresis and material shipment, reception of CAR-T cell drug and storing, CAR-T cell drug prescription and pharmacy verification, CAR-T cell drug thawing and dispensing, CAR-T cell drug administration, patient education, pharmacovigilance and monitoring and outcomes’ record and evaluation. In each task the pharmacist’s role and how it can improve patient care are defined. A checklist was created to guarantee the compliance of standard operating procedures approved in the institution to manage CAR-T cell therapy and as a tool to collect required data for outcomes’ record and evaluation.ConclusionThis article provides a consensus set of safety recommendations regarding CAR-T therapy management in clinical practice, easily implementable by other institutions in the European setting. The guide identifies key steps where the involvement of hospital pharmacists would improve the safety and quality of the process and is a support guide to standardize hospital pharmacists’ responsibilities within the multidisciplinary team.
Highlights
Chimeric antigen receptor T-cell therapies (CAR-T) are a type of advanced therapy based on the use of T lymphocytes to identify and kill tumor cells expressing a specific antigen
The two available CAR-T cell drugs use autologous T cells, which are collected in a leukapheresis process, sent to the manufacturer to be genetically modified to express the CAR and sent back to the treatment center to be reinfused into the patient, after they have received a lymphodepleting chemotherapy regimen [3]
The team created a checklist that helped with compliance along the processes and as a tool to collect required data to ensure traceability, efficacy and safety (Table 1)
Summary
Chimeric antigen receptor T-cell therapies (CAR-T) are a type of advanced therapy based on the use of T lymphocytes to identify and kill tumor cells expressing a specific antigen. This new type of immunotherapy consists of T lymphocytes that are genetically manipulated ex vivo to express engineered CARs specific for particular tumor targets. Tisagenlecleucel (Kymriah®, Novartis) and Axicabtagene ciloleucel (Yescarta®, Kite Pharma EU) were the first two CAR-T cell drugs authorized by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA) Both therapies target the B-lymphocyte antigen CD19 and are approved: tisagenlecleucel for pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma subtypes (DLBCL), and axicabtagene ciloleucel for DLBCL [1, 2]. The two available CAR-T cell drugs use autologous T cells, which are collected in a leukapheresis process, sent to the manufacturer to be genetically modified to express the CAR and sent back to the treatment center to be reinfused into the patient, after they have received a lymphodepleting chemotherapy regimen [3]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.